VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE

Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimmunology 2009-04, Vol.209 (1), p.6-15
Hauptverfasser: Roscoe, W.A, Welsh, M.E, Carter, D.E, Karlik, S.J
Format: Artikel
Sprache:eng
Schlagworte:
EAE
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15
container_issue 1
container_start_page 6
container_title Journal of neuroimmunology
container_volume 209
creator Roscoe, W.A
Welsh, M.E
Carter, D.E
Karlik, S.J
description Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increas
doi_str_mv 10.1016/j.jneuroim.2009.01.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67145673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0165572809000101</els_id><sourcerecordid>67145673</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</originalsourceid><addsrcrecordid>eNqFkc1O3DAQxy1UBMvHK6CcUHtIGH8muSAQWpaqIA60vVpeZwIO2WRrJ5W49R14Q54Eb3cREhcO1v_g38zYvyHkiEJGgaqTJms6HH3vFhkDKDOgWYwtMqFFztJCMPqFTCIoU5mzYpfshdAAUMlFuUN2ack4FwWfkB-_p7PLxHRVPPeuv8cOgwuJ6xJjxwH_39gH33fOJje3s69cvvx7lvJbssTl4CqMZDVarJLp-fSAbNemDXi4yX3y63L68-Iqvb6dfb84v05tfNaQKgplbuq8Li0IKxSARVnkdWGkKKRgJZtzBgp5YSo6V0JwyEtVYyVULWBu-D45Xvdd-v7PiGHQCxcstq3psB-DVjkVUuU8gmoNWt-H4LHWS-8Wxj9pCnqlUTf6TaNeadRAdYxYeLSZMM4XWL2XbbxF4GwNYPznX4deB-uwiyKcRzvoqnefzzj90MK2Lmo27SM-YWj60XfRoqY6MA36brXM1S6hhLhIoPwVfdmZpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67145673</pqid></control><display><type>article</type><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</creator><creatorcontrib>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</creatorcontrib><description><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2009.01.009</identifier><identifier>PMID: 19233483</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Alanyl aminopeptidase ; Allergy and Immunology ; Angiogenesis ; Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Angiogenic Proteins - genetics ; Animals ; Blood Vessels - drug effects ; Blood Vessels - metabolism ; Blood Vessels - pathology ; Caspase 8 ; Disease Models, Animal ; EAE ; Encephalomyelitis, Autoimmune, Experimental - drug therapy ; Encephalomyelitis, Autoimmune, Experimental - immunology ; Encephalomyelitis, Autoimmune, Experimental - metabolism ; Female ; Glycoproteins ; Hif1a ; Indoles - pharmacology ; Indoles - therapeutic use ; Laminin ; Laminin - drug effects ; Laminin - metabolism ; Mice ; Mice, Inbred C57BL ; MMP-19 ; Multiple sclerosis ; Myelin Sheath - drug effects ; Myelin Sheath - immunology ; Myelin Sheath - pathology ; Myelin-Oligodendrocyte Glycoprotein ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - physiopathology ; Neurology ; Peptide Fragments ; Plasminogen activator inhibitor ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Remyelination ; RNA, Messenger - drug effects ; RNA, Messenger - metabolism ; Spinal Cord - drug effects ; Spinal Cord - metabolism ; Spinal Cord - pathology ; SU5416 ; Thrombospondin ; Up-Regulation - drug effects ; Up-Regulation - physiology ; Vascular Endothelial Growth Factor A - antagonists &amp; inhibitors ; Vascular Endothelial Growth Factor A - metabolism ; Vascular Endothelial Growth Factor Receptor-2 - antagonists &amp; inhibitors ; Vascular Endothelial Growth Factor Receptor-2 - metabolism ; VEGF ; Wallerian Degeneration - chemically induced ; Wallerian Degeneration - pathology ; Wallerian Degeneration - physiopathology</subject><ispartof>Journal of neuroimmunology, 2009-04, Vol.209 (1), p.6-15</ispartof><rights>2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</citedby><cites>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165572809000101$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19233483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roscoe, W.A</creatorcontrib><creatorcontrib>Welsh, M.E</creatorcontrib><creatorcontrib>Carter, D.E</creatorcontrib><creatorcontrib>Karlik, S.J</creatorcontrib><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></description><subject>Alanyl aminopeptidase</subject><subject>Allergy and Immunology</subject><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Angiogenic Proteins - genetics</subject><subject>Animals</subject><subject>Blood Vessels - drug effects</subject><subject>Blood Vessels - metabolism</subject><subject>Blood Vessels - pathology</subject><subject>Caspase 8</subject><subject>Disease Models, Animal</subject><subject>EAE</subject><subject>Encephalomyelitis, Autoimmune, Experimental - drug therapy</subject><subject>Encephalomyelitis, Autoimmune, Experimental - immunology</subject><subject>Encephalomyelitis, Autoimmune, Experimental - metabolism</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Hif1a</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Laminin</subject><subject>Laminin - drug effects</subject><subject>Laminin - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>MMP-19</subject><subject>Multiple sclerosis</subject><subject>Myelin Sheath - drug effects</subject><subject>Myelin Sheath - immunology</subject><subject>Myelin Sheath - pathology</subject><subject>Myelin-Oligodendrocyte Glycoprotein</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - metabolism</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Neurology</subject><subject>Peptide Fragments</subject><subject>Plasminogen activator inhibitor</subject><subject>Pyrroles - pharmacology</subject><subject>Pyrroles - therapeutic use</subject><subject>Remyelination</subject><subject>RNA, Messenger - drug effects</subject><subject>RNA, Messenger - metabolism</subject><subject>Spinal Cord - drug effects</subject><subject>Spinal Cord - metabolism</subject><subject>Spinal Cord - pathology</subject><subject>SU5416</subject><subject>Thrombospondin</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - physiology</subject><subject>Vascular Endothelial Growth Factor A - antagonists &amp; inhibitors</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - antagonists &amp; inhibitors</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - metabolism</subject><subject>VEGF</subject><subject>Wallerian Degeneration - chemically induced</subject><subject>Wallerian Degeneration - pathology</subject><subject>Wallerian Degeneration - physiopathology</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1O3DAQxy1UBMvHK6CcUHtIGH8muSAQWpaqIA60vVpeZwIO2WRrJ5W49R14Q54Eb3cREhcO1v_g38zYvyHkiEJGgaqTJms6HH3vFhkDKDOgWYwtMqFFztJCMPqFTCIoU5mzYpfshdAAUMlFuUN2ack4FwWfkB-_p7PLxHRVPPeuv8cOgwuJ6xJjxwH_39gH33fOJje3s69cvvx7lvJbssTl4CqMZDVarJLp-fSAbNemDXi4yX3y63L68-Iqvb6dfb84v05tfNaQKgplbuq8Li0IKxSARVnkdWGkKKRgJZtzBgp5YSo6V0JwyEtVYyVULWBu-D45Xvdd-v7PiGHQCxcstq3psB-DVjkVUuU8gmoNWt-H4LHWS-8Wxj9pCnqlUTf6TaNeadRAdYxYeLSZMM4XWL2XbbxF4GwNYPznX4deB-uwiyKcRzvoqnefzzj90MK2Lmo27SM-YWj60XfRoqY6MA36brXM1S6hhLhIoPwVfdmZpQ</recordid><startdate>20090430</startdate><enddate>20090430</enddate><creator>Roscoe, W.A</creator><creator>Welsh, M.E</creator><creator>Carter, D.E</creator><creator>Karlik, S.J</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090430</creationdate><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><author>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alanyl aminopeptidase</topic><topic>Allergy and Immunology</topic><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Angiogenic Proteins - genetics</topic><topic>Animals</topic><topic>Blood Vessels - drug effects</topic><topic>Blood Vessels - metabolism</topic><topic>Blood Vessels - pathology</topic><topic>Caspase 8</topic><topic>Disease Models, Animal</topic><topic>EAE</topic><topic>Encephalomyelitis, Autoimmune, Experimental - drug therapy</topic><topic>Encephalomyelitis, Autoimmune, Experimental - immunology</topic><topic>Encephalomyelitis, Autoimmune, Experimental - metabolism</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Hif1a</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Laminin</topic><topic>Laminin - drug effects</topic><topic>Laminin - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>MMP-19</topic><topic>Multiple sclerosis</topic><topic>Myelin Sheath - drug effects</topic><topic>Myelin Sheath - immunology</topic><topic>Myelin Sheath - pathology</topic><topic>Myelin-Oligodendrocyte Glycoprotein</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - metabolism</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Neurology</topic><topic>Peptide Fragments</topic><topic>Plasminogen activator inhibitor</topic><topic>Pyrroles - pharmacology</topic><topic>Pyrroles - therapeutic use</topic><topic>Remyelination</topic><topic>RNA, Messenger - drug effects</topic><topic>RNA, Messenger - metabolism</topic><topic>Spinal Cord - drug effects</topic><topic>Spinal Cord - metabolism</topic><topic>Spinal Cord - pathology</topic><topic>SU5416</topic><topic>Thrombospondin</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - physiology</topic><topic>Vascular Endothelial Growth Factor A - antagonists &amp; inhibitors</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - antagonists &amp; inhibitors</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - metabolism</topic><topic>VEGF</topic><topic>Wallerian Degeneration - chemically induced</topic><topic>Wallerian Degeneration - pathology</topic><topic>Wallerian Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roscoe, W.A</creatorcontrib><creatorcontrib>Welsh, M.E</creatorcontrib><creatorcontrib>Carter, D.E</creatorcontrib><creatorcontrib>Karlik, S.J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roscoe, W.A</au><au>Welsh, M.E</au><au>Carter, D.E</au><au>Karlik, S.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2009-04-30</date><risdate>2009</risdate><volume>209</volume><issue>1</issue><spage>6</spage><epage>15</epage><pages>6-15</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19233483</pmid><doi>10.1016/j.jneuroim.2009.01.009</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-5728
ispartof Journal of neuroimmunology, 2009-04, Vol.209 (1), p.6-15
issn 0165-5728
1872-8421
language eng
recordid cdi_proquest_miscellaneous_67145673
source MEDLINE; Elsevier ScienceDirect Journals
subjects Alanyl aminopeptidase
Allergy and Immunology
Angiogenesis
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Angiogenic Proteins - genetics
Animals
Blood Vessels - drug effects
Blood Vessels - metabolism
Blood Vessels - pathology
Caspase 8
Disease Models, Animal
EAE
Encephalomyelitis, Autoimmune, Experimental - drug therapy
Encephalomyelitis, Autoimmune, Experimental - immunology
Encephalomyelitis, Autoimmune, Experimental - metabolism
Female
Glycoproteins
Hif1a
Indoles - pharmacology
Indoles - therapeutic use
Laminin
Laminin - drug effects
Laminin - metabolism
Mice
Mice, Inbred C57BL
MMP-19
Multiple sclerosis
Myelin Sheath - drug effects
Myelin Sheath - immunology
Myelin Sheath - pathology
Myelin-Oligodendrocyte Glycoprotein
Neovascularization, Pathologic - drug therapy
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - physiopathology
Neurology
Peptide Fragments
Plasminogen activator inhibitor
Pyrroles - pharmacology
Pyrroles - therapeutic use
Remyelination
RNA, Messenger - drug effects
RNA, Messenger - metabolism
Spinal Cord - drug effects
Spinal Cord - metabolism
Spinal Cord - pathology
SU5416
Thrombospondin
Up-Regulation - drug effects
Up-Regulation - physiology
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - metabolism
Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-2 - metabolism
VEGF
Wallerian Degeneration - chemically induced
Wallerian Degeneration - pathology
Wallerian Degeneration - physiopathology
title VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VEGF%20and%20angiogenesis%20in%20acute%20and%20chronic%20MOG(35%E2%80%9355)%20peptide%20induced%20EAE&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Roscoe,%20W.A&rft.date=2009-04-30&rft.volume=209&rft.issue=1&rft.spage=6&rft.epage=15&rft.pages=6-15&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2009.01.009&rft_dat=%3Cproquest_cross%3E67145673%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67145673&rft_id=info:pmid/19233483&rft_els_id=1_s2_0_S0165572809000101&rfr_iscdi=true